TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$25 Million

Ohr Pharmaceutical

Follow-on Offering

Sole Bookrunner, February 2015

Confidentially Marketed Public Offering

Ohr Pharmaceutical Inc is a US-based pharmaceutical company which focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. The lead product of the company is topical Squalamine is a novel therapeutic product which provides non-invasive therapy to improve visual outcomes. Its product pipeline includes SQUALAMINE LACTATE OPHTHALMIC SOLUTION 0.2%, SKS sustained release ocular drug delivery platform technology, Animal Model for Dry-AMD, and Non-Ophthalmology Assets.